Eramet SA securities enter pre-stabilisation period

Natixis announced a pre-stabilisation period for Eramet (EPA:ERMT) securities, managed by HSBC and Natixis, commencing today and lasting up to 30 days post the November 30, 2029, issue date; the managers may over-allot or transact to support the market price, though stabilisation is not guaranteed. The securities, with an aggregate nominal amount of EUR Benchmark, have an IPO price range of 97.75% to 98.00% and are to be traded OTC, targeting qualified investors in the EEA and UK, and specific individuals in the UK.

Analysis

Natixis has initiated a pre-stabilisation period for new securities of Eramet (EPA:ERMT) SA, with HSBC and Natixis serving as Stabilisation Managers. This period commenced today and can extend for up to 30 days following the designated issue date of November 30, 2029. During this timeframe, the managers are permitted to over-allot securities or conduct transactions aimed at supporting the market price of these securities above levels that might otherwise prevail, although there is no assurance that stabilisation activities will occur or continue if initiated. The securities are characterized by an aggregate nominal amount of EUR Benchmark, with an initial public offer price range set between 97.75% and 98.00% of nominal value, and are planned for over-the-counter (OTC) trading. This offering is specifically targeted at qualified investors within the European Economic Area (EEA) and the United Kingdom, certain professional and high net worth individuals in the UK, and persons outside the UK. Notably, the securities have not been registered under the United States Securities Act of 1933, precluding any public offering in the U.S. The announcement is purely informational, related to a future financial undertaking with a significantly distant issue date.

Key Decisions for Investors

• Eligible institutional investors tracking Eramet SA should note the planned issuance of new securities with a November 30, 2029 issue date and the associated pre-stabilisation mechanism, which could temporarily influence market prices immediately post-issuance.
• The indicative initial offer price range of 97.75% to 98.00% for these EUR Benchmark OTC-traded securities provides a preliminary valuation marker for this specific future offering, distinct from any currently trading Eramet instruments.
• Prospective investors must carefully verify their eligibility according to the specified jurisdictional criteria, particularly the exclusion of a U.S. public offering and the focus on qualified investors in the EEA and UK.
• Given the exceptionally long lead time until the 2029 issue date, this announcement serves as an early-stage notification; comprehensive due diligence on Eramet's financial condition and prevailing market sentiment will be crucial closer to the actual offering date.